Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) Shares Outstanding (Weighted Average) (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Shares Outstanding (Weighted Average) for 6 consecutive years, with $129.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 15.88% to $129.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $129.8 million, a 15.88% increase, with the full-year FY2025 number at $129.8 million, up 15.88% from a year prior.
  • Shares Outstanding (Weighted Average) was $129.8 million for Q4 2025 at TScan Therapeutics, roughly flat from $129.8 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $129.8 million in Q3 2025 to a low of $1.2 million in Q1 2021.
  • A 5-year average of $62.5 million and a median of $51.5 million in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): soared 1866.89% in 2022, then grew 1.05% in 2023.
  • TScan Therapeutics' Shares Outstanding (Weighted Average) stood at $11.7 million in 2021, then skyrocketed by 106.2% to $24.0 million in 2022, then skyrocketed by 172.78% to $65.6 million in 2023, then skyrocketed by 70.72% to $112.0 million in 2024, then increased by 15.88% to $129.8 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Shares Outstanding (Weighted Average) are $129.8 million (Q4 2025), $129.8 million (Q3 2025), and $129.7 million (Q2 2025).